Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Trial Profile

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Latanoprost/netarsudil (Primary) ; Latanoprost; Netarsudil
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Mercury 1
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2017 According to an Aerie Pharmaceuticals media release, a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled with the company for October 13, 2017 to review the NDA for Rhopressa (netarsudil ophthalmic solution) 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    • 08 Aug 2017 According to an Aerie Pharmaceuticals media release, data from this study and Rocket 4 were also included in the Rhopressa™ NDA submission as supportive.
    • 01 Aug 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top